Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
VVZ-149 is a novel analgesic drug candidate that shows a potential analgesic activity
inhibiting GlyT2 and 5HT2A simultaneously. These target receptors have been known to play
important roles in induction and transmission of pain signals. There have been many efforts
to develop selective drugs to treat pain, but usually unsuccessful due to the lack of
efficacy or limitations of single-target approach for new drug discovery. VVZ-149 is expected
to be a dual-target drug, demonstrated having a potential synergism between GlyT2 and 5HT2A
to maximize an antinociceptive effect in the in vivo animal models. In Phase 1 conducted
among healthy subjects, safety and tolerability were confirmed. Phase 2 was designed as a
randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy
and safety of the analgesic drug VVZ-149 injection.